Akari Therapeutics (AKTX) Goodwill & Intangibles (2014 - 2026)

Akari Therapeutics (AKTX) has reported Goodwill & Intangibles for 13 consecutive years, with $38.7 million the latest figure, recorded in Q1 2026.

• Quarterly Goodwill & Intangibles fell 18.65% year-over-year to $38.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.7 million (down 18.65% YoY) and the FY2025 annual result came in at $42.4 million, up 8.3% from the prior year.
• Goodwill & Intangibles slipped to $38.7 million in Q1 2026 per AKTX's latest filing, from $42.4 million in the prior quarter.
• Over the last five years, Goodwill & Intangibles for AKTX reached as high as $47.6 million in Q1 2025 and fell as low as $14000.0 in Q4 2023.
• A 5-year average of $25.0 million and a median of $36.4 million in 2025 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles slipped 26.24% — and 2024, when it surged 279757.14%.
• Year by year, Goodwill & Intangibles stood at $17000.0 in 2022, then dropped by 17.65% to $14000.0 in 2023, then jumped by 279757.14% to $39.2 million in 2024, then advanced by 8.3% to $42.4 million in 2025, then fell by 8.72% to $38.7 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $38.7 million, $42.4 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.